Brokerages Set Septerna, Inc. (NASDAQ:SEPN) PT at $33.83

Shares of Septerna, Inc. (NASDAQ:SEPN) have been given a consensus rating of “Moderate Buy” by the eight research firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $38.00.

A number of equities research analysts have commented on SEPN shares. Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a research report on Thursday, January 22nd. Wall Street Zen downgraded Septerna from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 10th. Zacks Research upgraded shares of Septerna from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. Truist Financial began coverage on shares of Septerna in a research report on Monday, December 15th. They set a “buy” rating and a $34.00 price objective on the stock. Finally, Raymond James Financial began coverage on shares of Septerna in a research note on Friday, December 19th. They issued a “strong-buy” rating and a $38.00 price objective on the stock.

Insider Buying and Selling at Septerna

In other news, COO Elizabeth Bhatt sold 4,000 shares of the company’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $28.97, for a total value of $115,880.00. Following the transaction, the chief operating officer directly owned 174,209 shares of the company’s stock, valued at approximately $5,046,834.73. This represents a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Samira Shaikhly sold 70,453 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $28.10, for a total value of $1,979,729.30. Following the sale, the insider owned 793 shares of the company’s stock, valued at approximately $22,283.30. This represents a 98.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Septerna

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Deutsche Bank AG grew its stake in shares of Septerna by 5.3% in the 4th quarter. Deutsche Bank AG now owns 14,879 shares of the company’s stock valued at $415,000 after buying an additional 744 shares in the last quarter. Global Retirement Partners LLC bought a new position in Septerna during the fourth quarter valued at approximately $35,000. Covestor Ltd raised its position in Septerna by 55.8% during the third quarter. Covestor Ltd now owns 3,620 shares of the company’s stock valued at $68,000 after acquiring an additional 1,296 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Septerna by 15.0% in the second quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock valued at $107,000 after acquiring an additional 1,315 shares during the last quarter. Finally, PharVision Advisers LLC lifted its stake in Septerna by 17.5% in the third quarter. PharVision Advisers LLC now owns 11,932 shares of the company’s stock valued at $224,000 after acquiring an additional 1,780 shares during the last quarter.

Septerna Stock Performance

Shares of SEPN stock traded up $1.31 on Friday, reaching $28.78. 302,190 shares of the company’s stock traded hands, compared to its average volume of 314,472. The company has a market capitalization of $1.29 billion, a P/E ratio of -19.06 and a beta of 3.46. Septerna has a 12-month low of $4.66 and a 12-month high of $32.63. The business’s 50 day moving average price is $26.88 and its two-hundred day moving average price is $22.85.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.